Orally active and selective benzylidene ketal M2 muscarinic receptor antagonists for the treatment of Alzheimer's disease
- 1 July 2002
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 56 (3) , 310-320
- https://doi.org/10.1002/ddr.10084
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Substituted 2-(R)-Methyl piperazines as muscarinic M2 selective ligandsBioorganic & Medicinal Chemistry Letters, 2002
- Nucleus Basalis of Meynert Pathology in the Human Brain after Fatal Head InjuryJournal of Neurotrauma, 2002
- Chronic Donepezil Treatment Is Associated with Slowed Cognitive Decline in Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2001
- Synthesis of New Cardioselective M2 Muscarinic Receptor Antagonists.CHEMICAL & PHARMACEUTICAL BULLETIN, 2000
- Synthesis and Biological Evaluation of Phenylacetyl Derivatives Having Low Central Nervous System Permeability as Potent and Selective M2 Muscarinic Receptor Antagonists.CHEMICAL & PHARMACEUTICAL BULLETIN, 1998
- A novel muscarinic receptor ligand which penetrates the blood brain barrier and displays in vivo selectivity for the m2 subtypeLife Sciences, 1993
- Therapeutic potential of CNS-active M2 antagonists: Novel structures and pharmacologyLife Sciences, 1993
- Selectivity of pirenzepine in the central nervous system. II. Differential effects of pirenzepine and scopolamine on performance of a representational memory taskBrain Research, 1987
- Cardioselective profile of AF-DX 116, a muscarine M2 receptor antagonistLife Sciences, 1986
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982